AstraZeneca Sues Utah Over Controversial Drug Pricing Law
AstraZeneca, one of the world’s largest pharmaceutical companies, has filed a lawsuit against Utah Attorney General Derek Brown, challenging the constitutionality of SB69, a newly enacted law facilitating hospitals, clinics, and pharmacies’ access to discounted drugs. The lawsuit, which was filed in U.S. District Court last month, also names Utah Insurance Commissioner Jon Pike.
Sponsored by Sen. Evan Vickers (R-Cedar City), SB69 aims to empower 340B entities—healthcare organizations participating in the 340B Drug Pricing Program—to purchase outpatient medications at significantly reduced prices. Advocates for the law argue it enhances access to affordable healthcare for underserved populations by preventing major drug companies from restricting where these facilities can obtain discounted medicines.
The law was motivated by concerns that pharmaceutical giants were limiting 340B entities’ purchasing options, thereby impacting their ability to serve vulnerable communities. As the case progresses, it highlights ongoing tensions between pharmaceutical companies and state regulations aimed at improving drug accessibility. The outcome could significantly influence how discounted medications are sourced in the future.
Note: The image is for illustrative purposes only and is not the original image associated with the presented article. Due to copyright reasons, we are unable to use the original images. However, you can still enjoy the accurate and up-to-date content and information provided.
